Yuan Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yuan Jiang has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey T. Fong
School of Psychology, University of Waterloo, Waterloo, Ontario, Canada
7 shared publications - Anne Chiew Kin Quah
School of Psychology, University of Waterloo, Waterloo, Ontario, Canada
4 shared publications - David Hammond
School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada
4 shared publications - Guo-Ze Feng
Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
4 shared publications - Hua-Hie Yong
School of Psychology, Deakin University, Geelong, Victoria, Australia
4 shared publications Shuai Kong
Hefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science Chinese Academy of Sciences Hefei China
4 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in Cell Proliferation
TEAD1 Super‐Enhancer‐Mediated Transcriptional Dysregulation Confers Vulnerability in Nasopharyngeal Carcinoma
Transcriptional dysregulation underlying nasopharyngeal carcinoma (NPC) progression remains incompletely characterized, limiting the development of targeted therapies. In this study, we systematically characterized the cis ‐regulatory landscape of NPC cells and identified TEAD1 as a super‐enhancer‐associated transcription factor. Elevated TEAD1 expression promotes NPC cell proliferation and tumour growth and correlates with advanced NPC stages and adverse clinical outcomes. Mechanistically, the TEAD1‐associated super‐enhancer architecture contributes to elevated TEAD1 expression. Moreover, the newly identified TEAD1 ‐associated transcriptional co‐regulator ILF3 (interleukin enhancer binding factor 3) cooperates with TEAD1 to maintain chromatin accessibility at a subset of TEAD1‐bound regions and support TEAD1‐dependent transcription programmes, thereby activating RTK‐MAPK and PI3K‐AKT signalling cascades. Pharmacological inhibition of TEAD activity with VT103 enhanced the antitumor effect of gemcitabine in NPC models. Our findings identify a TEAD1‐governed transcriptional dysregulation mechanism in NPC, which provides a rationale for further investigation of TEAD1 as a prognostic biomarker and therapeutic target.
- 18 November 2026
- Published by Wiley in Cell Proliferation
Open AccessTEAD1 Super‐Enhancer‐Mediated Transcriptional Dysregulation Confers Vulnerability in Nasopharyngeal Carcinoma
Transcriptional dysregulation underlying nasopharyngeal carcinoma (NPC) progression remains incompletely characterized, limiting the development of targeted therapies. In this study, we systematically characterized the cis ‐regulatory landscape of NPC cells and identified TEAD1 as a super‐enhancer‐associated transcription factor. Elevated TEAD1 expression promotes NPC cell proliferation and tumour growth and correlates with advanced NPC stages and adverse clinical outcomes. Mechanistically, the TEAD1‐associated super‐enhancer architecture contributes to elevated TEAD1 expression. Moreover, the newly identified TEAD1 ‐associated transcriptional co‐regulator ILF3 (interleukin enhancer binding factor 3) cooperates with TEAD1 to maintain chromatin accessibility at a subset of TEAD1‐bound regions and support TEAD1‐dependent transcription programmes, thereby activating RTK‐MAPK and PI3K‐AKT signalling cascades. Pharmacological inhibition of TEAD activity with VT103 enhanced the antitumor effect of gemcitabine in NPC models. Our findings identify a TEAD1‐governed transcriptional dysregulation mechanism in NPC, which provides a rationale for further investigation of TEAD1 as a prognostic biomarker and therapeutic target.
- 31 August 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (10) , 5213-5230
HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma
- 31 August 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (10) , 5213-5230
HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma
- Open Access
High glucose confers senescence resistance via GLUT1 epigenetic rewiring to blunt immunotherapy responses in esophageal squamous cell carcinoma
Therapeutic resistance and undefined predictive biomarkers severely hinder the clinical popularization of immunotherapy in esophageal squamous cell carcinoma (ESCC). Herein, we identify the glucose transporter 1 (GLUT1) as a critical determinant of immunotherapy resistance. Elevated expression of GLUT1 correlates with poor immunotherapy response and unfavorable prognosis in ESCC patients. GLUT1 deletion or inhibition enhances CD8⁺ T cell infiltration and cytotoxicity, and sensitizes ESCC tumors to anti-PD-1 (α-PD1) therapy. Importantly, dietary glucose restriction exhibits equivalent antitumor efficacy to GLUT1 inhibition when combined with α-PD1. Mechanistically, GLUT1 establishes a positive feedback loop with HAT1 and FOXM1, which epigenetically remodels chromatin accessibility to suppress tumor cell senescence, thereby impeding CD8⁺ T cell-mediated antitumor immunity. Our findings highlight GLUT1 as a predictive biomarker of immunotherapy resistance and suggest dietary glucose restriction as a viable strategy to potentiate immunotherapy efficacy in ESCC. Graphical SHORT SUMMARY: Dong et al. identify glucose transporter 1 (GLUT1) as a predictor of poor response to immunotherapy in esophageal squamous cell carcinoma. GLUT1 promotes immune evasion by forming a positive feedback loop with the HAT1/FOXM1 anti-senescence axis, thereby epigenetically remodeling chromatin accessibility. GLUT1 inhibition or dietary glucose restriction restores CD8⁺ T-cell-mediated antitumor immunity and improves the efficacy of anti-PD-1 therapy in preclinical models.
Open AccessHigh glucose confers senescence resistance via GLUT1 epigenetic rewiring to blunt immunotherapy responses in esophageal squamous cell carcinoma
Therapeutic resistance and undefined predictive biomarkers severely hinder the clinical popularization of immunotherapy in esophageal squamous cell carcinoma (ESCC). Herein, we identify the glucose transporter 1 (GLUT1) as a critical determinant of immunotherapy resistance. Elevated expression of GLUT1 correlates with poor immunotherapy response and unfavorable prognosis in ESCC patients. GLUT1 deletion or inhibition enhances CD8⁺ T cell infiltration and cytotoxicity, and sensitizes ESCC tumors to anti-PD-1 (α-PD1) therapy. Importantly, dietary glucose restriction exhibits equivalent antitumor efficacy to GLUT1 inhibition when combined with α-PD1. Mechanistically, GLUT1 establishes a positive feedback loop with HAT1 and FOXM1, which epigenetically remodels chromatin accessibility to suppress tumor cell senescence, thereby impeding CD8⁺ T cell-mediated antitumor immunity. Our findings highlight GLUT1 as a predictive biomarker of immunotherapy resistance and suggest dietary glucose restriction as a viable strategy to potentiate immunotherapy efficacy in ESCC. Graphical SHORT SUMMARY: Dong et al. identify glucose transporter 1 (GLUT1) as a predictor of poor response to immunotherapy in esophageal squamous cell carcinoma. GLUT1 promotes immune evasion by forming a positive feedback loop with the HAT1/FOXM1 anti-senescence axis, thereby epigenetically remodeling chromatin accessibility. GLUT1 inhibition or dietary glucose restriction restores CD8⁺ T-cell-mediated antitumor immunity and improves the efficacy of anti-PD-1 therapy in preclinical models.
- Open Access
- 19 May 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Disrupting MED8-dependent epigenetic reprogramming augments avapritinib sensitivity in PDGFRA-driven glioma
Background: PDGFRA genetic alterations are a well-established oncogenic driver in gliomas. However, targeted monotherapy against PDGFRA such as avapritinib has achieved limited clinical efficacy, and the mechanism underlying avapritinib resistance remains poorly understood. Methods: Multi-omics analysis of clinical samples identified super-enhancer (SE) complex components. Comprehensive preclinical evaluation was performed using glioma cell lines, glioma stem cells, patient-derived cells, xenografts, and organoids. Mechanistic investigations integrated Cleavage Under Targets and Tagmentation, chromatin immunoprecipitation, co-immunoprecipitation, mass spectrometry, protein fragment complementation, and dual-luciferase reporter assays. Results: Functional and clinical analyses identified the SE complex component MED8 as significantly upregulated in gliomas and correlated with poor prognosis. MED8 was essential for tumor proliferation and survival both in vitro and in vivo. Mechanistically, MED8 cooperated with CDK7 to bind and activate the SEs of PDGFRA, sustaining high transcriptional output of this oncogene. We repurposed FDA-approved venetoclax as a first-in-class MED8-targeting agent that potently sensitizes to avapritinib, exerting synergistic effects in multiple preclinical models. Conclusions: This study delineates a novel MED8-SE-PDGFRA epigenetic axis driving resistance. The combination of avapritinib and venetoclax, co-targeting the oncogenic signal and its transcriptional regulator, presents a translatable dual-targeting strategy to improve outcomes in PDGFRA-driven glioma.
- 19 May 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessDisrupting MED8-dependent epigenetic reprogramming augments avapritinib sensitivity in PDGFRA-driven glioma
Background: PDGFRA genetic alterations are a well-established oncogenic driver in gliomas. However, targeted monotherapy against PDGFRA such as avapritinib has achieved limited clinical efficacy, and the mechanism underlying avapritinib resistance remains poorly understood. Methods: Multi-omics analysis of clinical samples identified super-enhancer (SE) complex components. Comprehensive preclinical evaluation was performed using glioma cell lines, glioma stem cells, patient-derived cells, xenografts, and organoids. Mechanistic investigations integrated Cleavage Under Targets and Tagmentation, chromatin immunoprecipitation, co-immunoprecipitation, mass spectrometry, protein fragment complementation, and dual-luciferase reporter assays. Results: Functional and clinical analyses identified the SE complex component MED8 as significantly upregulated in gliomas and correlated with poor prognosis. MED8 was essential for tumor proliferation and survival both in vitro and in vivo. Mechanistically, MED8 cooperated with CDK7 to bind and activate the SEs of PDGFRA, sustaining high transcriptional output of this oncogene. We repurposed FDA-approved venetoclax as a first-in-class MED8-targeting agent that potently sensitizes to avapritinib, exerting synergistic effects in multiple preclinical models. Conclusions: This study delineates a novel MED8-SE-PDGFRA epigenetic axis driving resistance. The combination of avapritinib and venetoclax, co-targeting the oncogenic signal and its transcriptional regulator, presents a translatable dual-targeting strategy to improve outcomes in PDGFRA-driven glioma.
- 24 July 2025
- Published by Springer Nature in AIDS and Behavior
- Vol. 29 (12) , 3866-3876
WeChat-based Messaging and Behavioral Counseling for Smoking Cessation for People with HIV in China: a Randomized Controlled Pilot Trial
Cigarette smoking among people with HIV is a leading preventable cause of morbidity and mortality, particularly in China given its immense burden of smoking. This pilot study aimed to evaluate the feasibility, acceptability, and efficacy on smoking cessation of a community-informed WeChat-based messaging and behavioral counseling intervention for people with HIV who smoke called Quit for Life. The study design was a 2-group randomized clinical trial. Data collection occurred between February 2022 and August 2023 within a tertiary infectious disease hospital in Nanning city, Guangxi, China. Participants included adults with HIV who smoked, were willing to set a quit date, and received HIV care at the hospital. Participants were randomized to the 8-week Quit for Life intervention group (nicotine replacement therapy gum, self-help quitting smoking guide, behavioral counseling, and WeChat-based messaging), or the control group (nicotine replacement therapy gum and self-help guide only). Complete case analysis was performed. Of 219 people assessed for eligibility, 109 participants were randomized (mean [SD] age, 45.3 [15.1] years; men [96.3%]) and 98 completed the 12-week assessment (89.9% retention rate). At 12-week follow-up, the biochemically verified smoking cessation rate (primary outcome) was significantly higher in the intervention group compared to the control group (59.1% abstinence vs. 25.6%, adjusted odds ratio 5.3 [1.5,19.2]. Implementation and feasibility metrics indicated most participants receiving the intervention as intended gave high ratings of the usefulness of counseling sessions and WeChat-based messaging. Given these findings, subsequent studies should investigate implementation and scale-up of this intervention for people with HIV in China. Clinical trial registration details: Trial registration number: ClinicalTrials.gov Identifier: NCT05020899. Date of trial registration: 8-19-2021.
- 24 July 2025
- Published by Springer Nature in AIDS and Behavior
- Vol. 29 (12) , 3866-3876
WeChat-based Messaging and Behavioral Counseling for Smoking Cessation for People with HIV in China: a Randomized Controlled Pilot Trial
Cigarette smoking among people with HIV is a leading preventable cause of morbidity and mortality, particularly in China given its immense burden of smoking. This pilot study aimed to evaluate the feasibility, acceptability, and efficacy on smoking cessation of a community-informed WeChat-based messaging and behavioral counseling intervention for people with HIV who smoke called Quit for Life. The study design was a 2-group randomized clinical trial. Data collection occurred between February 2022 and August 2023 within a tertiary infectious disease hospital in Nanning city, Guangxi, China. Participants included adults with HIV who smoked, were willing to set a quit date, and received HIV care at the hospital. Participants were randomized to the 8-week Quit for Life intervention group (nicotine replacement therapy gum, self-help quitting smoking guide, behavioral counseling, and WeChat-based messaging), or the control group (nicotine replacement therapy gum and self-help guide only). Complete case analysis was performed. Of 219 people assessed for eligibility, 109 participants were randomized (mean [SD] age, 45.3 [15.1] years; men [96.3%]) and 98 completed the 12-week assessment (89.9% retention rate). At 12-week follow-up, the biochemically verified smoking cessation rate (primary outcome) was significantly higher in the intervention group compared to the control group (59.1% abstinence vs. 25.6%, adjusted odds ratio 5.3 [1.5,19.2]. Implementation and feasibility metrics indicated most participants receiving the intervention as intended gave high ratings of the usefulness of counseling sessions and WeChat-based messaging. Given these findings, subsequent studies should investigate implementation and scale-up of this intervention for people with HIV in China. Clinical trial registration details: Trial registration number: ClinicalTrials.gov Identifier: NCT05020899. Date of trial registration: 8-19-2021.
- 25 January 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (15) , 1037-1050
Targeting aldehyde dehydrogenase ALDH3A1 increases ferroptosis vulnerability in squamous cancer
Ferroptosis is a unique modality of regulated cell death induced by excessive lipid peroxidation, playing a crucial role in tumor suppression and providing potential therapeutic strategy for cancer treatment. Here, we find that aldehyde dehydrogenase-ALDH3A1 tightly links to ferroptosis in squamous cell carcinomas (SCCs). Functional assays demonstrate the enzymatic activity-dependent regulation of ALDH3A1 in protecting SCC cells against ferroptosis through catalyzing aldehydes and mitigating lipid peroxidation. Furthermore, a specific covalent inhibitor of ALDH3A1-EN40 significantly enhances the ferroptosis sensitivity induced by the ferroptosis inducer. The combination of EN40 and a ferroptosis inducer exhibits a synergistic effect, effectively inhibiting the proliferation of SCC cells/organoids and suppressing tumor growth both in vitro and in vivo. On mechanism, high expression of ALDH3A1 is transcriptionally governed by TP63, which binds to super-enhancer of ALDH3A1. Collectively, our findings reveal a yet-unrecognized function of ALDH3A1 exploited by SCC cells to evade ferroptosis, and targeting ALDH3A1 may enhance the effect of ferroptosis-induced therapy in SCCs.
- 25 January 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (15) , 1037-1050
Targeting aldehyde dehydrogenase ALDH3A1 increases ferroptosis vulnerability in squamous cancer
Ferroptosis is a unique modality of regulated cell death induced by excessive lipid peroxidation, playing a crucial role in tumor suppression and providing potential therapeutic strategy for cancer treatment. Here, we find that aldehyde dehydrogenase-ALDH3A1 tightly links to ferroptosis in squamous cell carcinomas (SCCs). Functional assays demonstrate the enzymatic activity-dependent regulation of ALDH3A1 in protecting SCC cells against ferroptosis through catalyzing aldehydes and mitigating lipid peroxidation. Furthermore, a specific covalent inhibitor of ALDH3A1-EN40 significantly enhances the ferroptosis sensitivity induced by the ferroptosis inducer. The combination of EN40 and a ferroptosis inducer exhibits a synergistic effect, effectively inhibiting the proliferation of SCC cells/organoids and suppressing tumor growth both in vitro and in vivo. On mechanism, high expression of ALDH3A1 is transcriptionally governed by TP63, which binds to super-enhancer of ALDH3A1. Collectively, our findings reveal a yet-unrecognized function of ALDH3A1 exploited by SCC cells to evade ferroptosis, and targeting ALDH3A1 may enhance the effect of ferroptosis-induced therapy in SCCs.
- Open Access
- 19 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1330785
Perioperative immunotherapy for esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological subtype and accounts for 85% of esophageal cancer cases worldwide. Traditional treatment for ESCC involves chemotherapy, radiotherapy, and surgery. However, the overall prognosis remains unfavorable. Recently, immune checkpoint blockade (ICB) therapy using anti-programmed cell death-1 (PD-1)/PD-1 ligand (PD-L1) antibodies have not only achieved remarkable benefits in the clinical management of ESCC but have also completely changed the treatment approach for this cancer. In just a few years, ICB therapy has rapidly advanced and been added to standard first-line treatment regimen in patients with ESCC. However, preoperative immunotherapy is yet to be approved. In this review, we summarize the ICB antibodies commonly used in clinical immunotherapy of ESCC, and discuss the advances of immunotherapy combined with chemotherapy and radiotherapy in the perioperative treatment of ESCC, aiming to provide reference for clinical management of ESCC patients across the whole course of treatment.
- 19 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1330785
Open AccessPerioperative immunotherapy for esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological subtype and accounts for 85% of esophageal cancer cases worldwide. Traditional treatment for ESCC involves chemotherapy, radiotherapy, and surgery. However, the overall prognosis remains unfavorable. Recently, immune checkpoint blockade (ICB) therapy using anti-programmed cell death-1 (PD-1)/PD-1 ligand (PD-L1) antibodies have not only achieved remarkable benefits in the clinical management of ESCC but have also completely changed the treatment approach for this cancer. In just a few years, ICB therapy has rapidly advanced and been added to standard first-line treatment regimen in patients with ESCC. However, preoperative immunotherapy is yet to be approved. In this review, we summarize the ICB antibodies commonly used in clinical immunotherapy of ESCC, and discuss the advances of immunotherapy combined with chemotherapy and radiotherapy in the perioperative treatment of ESCC, aiming to provide reference for clinical management of ESCC patients across the whole course of treatment.
- Open Access
- 1 January 2020
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 2 (23) , 426-427
Urgent Need to Ratify National Legislation Banning Smoking in Public Places
- 1 January 2020
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 2 (23) , 426-427
Open AccessUrgent Need to Ratify National Legislation Banning Smoking in Public Places
- Open Access
- 3 April 2019
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 16 (7) , 1205
Cigarette Affordability in China, 2006–2015: Findings from International Tobacco Control China Surveys
China is world’s largest market of machine-made cigarettes. In 2015, more than 315 million or around 26.9% of the adult population in China were smokers—50.6% among men and 2.2% among women. Growing affordability of cigarettes led to increased cigarette consumption in China to the detriment of public health. This study investigated whether the level and growth in cigarette affordability in China was equally shared by smokers from all demographic and socio-economic statuses (SES) and across all price tiers of cigarette brands. The data came from the urban smoker sample (≥18 years) of the International Tobacco Control China Surveys conducted in five waves over 2006–2015. Cigarette affordability was measured by Relative Income Price—percentage of per capita household income needed to purchase 100 cigarette packs of the last purchased brand. Overall and group-specific trends in affordability by age, gender, SES (e.g., income, education, and employment status), and price tiers were analyzed using generalized estimating equations method. Cigarette affordability was higher among older, female, and higher-SES smokers, and for cheaper brands. It increased overall and across all groups over time. The increase was significantly larger among younger and lower-SES smokers, a trend that poses an added challenge to tobacco control and health equity. To reduce cigarette affordability and consumption among these vulnerable groups, a uniform specific excise system should be introduced in place of the existing tiered ad valorem excise. The specific excise should be periodically adjusted to inflation and per capita income growth observed among younger and lower-SES people, who can potentially experience faster income growth than the national average. The excise tax policy can also be complimented with minimum price regulations and restrictions on price promotions.
- 3 April 2019
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 16 (7) , 1205
Open AccessCigarette Affordability in China, 2006–2015: Findings from International Tobacco Control China Surveys
China is world’s largest market of machine-made cigarettes. In 2015, more than 315 million or around 26.9% of the adult population in China were smokers—50.6% among men and 2.2% among women. Growing affordability of cigarettes led to increased cigarette consumption in China to the detriment of public health. This study investigated whether the level and growth in cigarette affordability in China was equally shared by smokers from all demographic and socio-economic statuses (SES) and across all price tiers of cigarette brands. The data came from the urban smoker sample (≥18 years) of the International Tobacco Control China Surveys conducted in five waves over 2006–2015. Cigarette affordability was measured by Relative Income Price—percentage of per capita household income needed to purchase 100 cigarette packs of the last purchased brand. Overall and group-specific trends in affordability by age, gender, SES (e.g., income, education, and employment status), and price tiers were analyzed using generalized estimating equations method. Cigarette affordability was higher among older, female, and higher-SES smokers, and for cheaper brands. It increased overall and across all groups over time. The increase was significantly larger among younger and lower-SES smokers, a trend that poses an added challenge to tobacco control and health equity. To reduce cigarette affordability and consumption among these vulnerable groups, a uniform specific excise system should be introduced in place of the existing tiered ad valorem excise. The specific excise should be periodically adjusted to inflation and per capita income growth observed among younger and lower-SES people, who can potentially experience faster income growth than the national average. The excise tax policy can also be complimented with minimum price regulations and restrictions on price promotions.
- Open Access
Association of Smoking Prevalence and Alcohol Use with Risk of Lung Cancer: Ecological Evidence
Background: Smoking and alcohol use are two common behaviors that affect human health. However, few studies have examined their association with risk of lung cancer with ecological data. Methods: The dependent variable was the estimate of world agestandardized incidence of lung cancer in 2018. Independent variables included the smoking prevalence by gender in 2010 and 2000, which considered potential latency of lung cancer, the rate of alcohol use by gender in 2010, and the gross domestic product (GDP) per capita in 2010 and 2000. A linear regression model was used for statistical data analysis. Results: Both simple and multiple linear regression analysis showed that the prevalence of women's smoking affected the incidence of lung cancer overall (t = 4.96; P < 0.0001), in men (t = 4.56; P < 0.0001) and in women (t = 3.22; P < 0.0001) even when socioeconomic development measured by the GDP per capita was adjusted. These associations were consistent in the overall (t = 4.59; P < 0.0001) and men (t = 3.37; P = 0.001), but stronger in women (t = 4.67; P < 0.0001) when the estimates of smoking prevalence in 2000 were used; and the GDP per capita was significantly associated with the incidence of lung cancer as well. Interestingly, the ratio of smoking prevalence between men and women in 2000 explained about 10% (P = 0.0006; R 2 = 0.097) of the variation in the ratio of lung cancer incidence between men and women even after adjusting for socioeconomic development. However, we did not find an association of alcohol use with the incidence of lung cancer at an aggregated level. Conclusion: At an aggregated level, the women's smoking prevalence is associated with the incidence of lung cancer and gender difference in smoking is associated with the ratio of lung cancer incidence between men and women, providing strong evidence for the relationship of smoking and lung cancer.
Open AccessAssociation of Smoking Prevalence and Alcohol Use with Risk of Lung Cancer: Ecological Evidence
Background: Smoking and alcohol use are two common behaviors that affect human health. However, few studies have examined their association with risk of lung cancer with ecological data. Methods: The dependent variable was the estimate of world agestandardized incidence of lung cancer in 2018. Independent variables included the smoking prevalence by gender in 2010 and 2000, which considered potential latency of lung cancer, the rate of alcohol use by gender in 2010, and the gross domestic product (GDP) per capita in 2010 and 2000. A linear regression model was used for statistical data analysis. Results: Both simple and multiple linear regression analysis showed that the prevalence of women's smoking affected the incidence of lung cancer overall (t = 4.96; P < 0.0001), in men (t = 4.56; P < 0.0001) and in women (t = 3.22; P < 0.0001) even when socioeconomic development measured by the GDP per capita was adjusted. These associations were consistent in the overall (t = 4.59; P < 0.0001) and men (t = 3.37; P = 0.001), but stronger in women (t = 4.67; P < 0.0001) when the estimates of smoking prevalence in 2000 were used; and the GDP per capita was significantly associated with the incidence of lung cancer as well. Interestingly, the ratio of smoking prevalence between men and women in 2000 explained about 10% (P = 0.0006; R 2 = 0.097) of the variation in the ratio of lung cancer incidence between men and women even after adjusting for socioeconomic development. However, we did not find an association of alcohol use with the incidence of lung cancer at an aggregated level. Conclusion: At an aggregated level, the women's smoking prevalence is associated with the incidence of lung cancer and gender difference in smoking is associated with the ratio of lung cancer incidence between men and women, providing strong evidence for the relationship of smoking and lung cancer.